Smart-Money SignalNeutral · 44/100— Insiders are net sellers over 90 days (-$51K, 4 sales vs 4 buys)
Revenue$398.0K
Net Income-$4.7M
EPS$-0.19
Gross Margin66.3%
Price Performance
Historical data including institutional events
Company Profile
S
Stephen Willard
CEO & Executive Director
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimerâs disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
